Tumour budding is a novel marker in breast cancer: the clinical application and future prospects
Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical fac...
Saved in:
| Published in | Annals of medicine (Helsinki) Vol. 54; no. 1; pp. 1303 - 1312 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Taylor & Francis
31.12.2022
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical factor for poor prognosis in BC patients. Tumour budding (TB) is considered as the first step process of tumour metastasis and is related to the epithelial-mesenchymal transition (EMT). TB has been observed in a variety of cancers, such as colorectal and gastric cancer, and had been considered as a distinct clinicopathological characteristics for early metastasis. However, TB evaluation standards and clinical application are not uniform in BC, as well as its molecular mechanism is not fully understood. Here, we reviewed the interpretation criteria, mechanism, clinicopathological characteristics and clinical application prospects of TB in BC.
Key messages
Currently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer.
Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process.
Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer. |
|---|---|
| AbstractList | Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical factor for poor prognosis in BC patients. Tumour budding (TB) is considered as the first step process of tumour metastasis and is related to the epithelial–mesenchymal transition (EMT). TB has been observed in a variety of cancers, such as colorectal and gastric cancer, and had been considered as a distinct clinicopathological characteristics for early metastasis. However, TB evaluation standards and clinical application are not uniform in BC, as well as its molecular mechanism is not fully understood. Here, we reviewed the interpretation criteria, mechanism, clinicopathological characteristics and clinical application prospects of TB in BC.
Key messages
Currently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer.
Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process.
Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer. Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical factor for poor prognosis in BC patients. Tumour budding (TB) is considered as the first step process of tumour metastasis and is related to the epithelial–mesenchymal transition (EMT). TB has been observed in a variety of cancers, such as colorectal and gastric cancer, and had been considered as a distinct clinicopathological characteristics for early metastasis. However, TB evaluation standards and clinical application are not uniform in BC, as well as its molecular mechanism is not fully understood. Here, we reviewed the interpretation criteria, mechanism, clinicopathological characteristics and clinical application prospects of TB in BC. Key messagesCurrently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer.Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process.Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer. Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical factor for poor prognosis in BC patients. Tumour budding (TB) is considered as the first step process of tumour metastasis and is related to the epithelial-mesenchymal transition (EMT). TB has been observed in a variety of cancers, such as colorectal and gastric cancer, and had been considered as a distinct clinicopathological characteristics for early metastasis. However, TB evaluation standards and clinical application are not uniform in BC, as well as its molecular mechanism is not fully understood. Here, we reviewed the interpretation criteria, mechanism, clinicopathological characteristics and clinical application prospects of TB in BC. Key messagesCurrently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer.Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process.Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer.Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological characteristics, leading to significantly different prognosis. Despite significant advances in the treatment of BC, early metastatic is a critical factor for poor prognosis in BC patients. Tumour budding (TB) is considered as the first step process of tumour metastasis and is related to the epithelial-mesenchymal transition (EMT). TB has been observed in a variety of cancers, such as colorectal and gastric cancer, and had been considered as a distinct clinicopathological characteristics for early metastasis. However, TB evaluation standards and clinical application are not uniform in BC, as well as its molecular mechanism is not fully understood. Here, we reviewed the interpretation criteria, mechanism, clinicopathological characteristics and clinical application prospects of TB in BC. Key messagesCurrently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer.Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process.Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer. |
| Author | Zhu, Jian-lin Bao, Hui Meng, Yu-hua Huang, Ting Chu, Xiao-dong Chu, Xiao-li Pan, Jing-hua |
| Author_xml | – sequence: 1 givenname: Ting surname: Huang fullname: Huang, Ting organization: Department of Clinical Pathology, the First Affiliated Hospital of Jinan University – sequence: 2 givenname: Hui surname: Bao fullname: Bao, Hui organization: Department of Plastic Surgery, the First Affiliated Hospital of Jinan University – sequence: 3 givenname: Yu-hua surname: Meng fullname: Meng, Yu-hua organization: Department of Clinical Pathology, the First People's Hospital of Shunde – sequence: 4 givenname: Jian-lin surname: Zhu fullname: Zhu, Jian-lin organization: Department of General Surgery, the First Affiliated Hospital of Jinan University – sequence: 5 givenname: Xiao-dong surname: Chu fullname: Chu, Xiao-dong organization: Department of General Surgery, the First Affiliated Hospital of Jinan University – sequence: 6 givenname: Xiao-li surname: Chu fullname: Chu, Xiao-li organization: Guangdong Provincial Key laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases – sequence: 7 givenname: Jing-hua surname: Pan fullname: Pan, Jing-hua organization: Department of General Surgery, the First Affiliated Hospital of Jinan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35535687$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUsluFDEQtVAQmQQ-AeQjlwle2r2AhEARS6RIXOZuvFRPHDx2Y7uD8ve4M5OIcICLbVW9peR6J-goxAAIvaTkjJKevCFdL3g_kDNGGKtHR1jHnqAV5a1YM9KSI7RaMOsFdIxOcr4mpGIoeYaOuRBctH23Qt838y7OCevZWhe22GWscIg34PFOpR-QsAtYJ1C5YKOCgfQWlyvAxrvgjPJYTZOvj-JiwCpYPM5lToCnFPMEpuTn6OmofIYXh_sUbT5_2px_XV9--3Jx_vFybQRvyroZxrHTQkOjGmvZSFsggwULA-iOAu11U9uj6ploh14zpQUVoBtmeEtGy0_RxV7WRnUtp-Tq9LcyKifvCjFtpUrFGQ-yVXRoelZNtGoYs4NogPGGKwtdHYBWrfd7rWnWO7AGQknKPxJ93AnuSm7jjRwo4azrqsDrg0CKP2fIRe5cNuC9ChDnLFnb0kEIOixer_70ejC531AFiD3A1B_NCcYHCCVySYK8T4JckiAPSai8d3_xjCt3a6ojO_9f9oc924Uxpp36FZO3sqhbH9OYag5clvzfEr8BCmfN5g |
| CitedBy_id | crossref_primary_10_1002_cncr_35261 crossref_primary_10_1016_j_anndiagpath_2023_152128 crossref_primary_10_3390_biomedicines11112906 crossref_primary_10_3390_cancers15061704 crossref_primary_10_1016_j_prp_2024_155424 crossref_primary_10_1007_s10142_023_00963_y crossref_primary_10_1080_1354750X_2024_2415078 crossref_primary_10_3390_biom14080896 crossref_primary_10_12688_f1000research_142427_1 crossref_primary_10_1055_s_0044_1789582 crossref_primary_10_1021_acsabm_2c00749 crossref_primary_10_1002_advs_202401041 crossref_primary_10_1016_j_jrras_2023_100620 crossref_primary_10_1007_s40944_023_00769_7 crossref_primary_10_7759_cureus_70315 crossref_primary_10_1590_1806_9282_20230191 crossref_primary_10_1016_j_yexcr_2022_113452 crossref_primary_10_1177_2632010X241235543 crossref_primary_10_17650_1994_4098_2024_16_2_83_89 crossref_primary_10_1186_s42047_025_00181_9 crossref_primary_10_3390_ijms242015332 |
| Cites_doi | 10.1016/j.prp.2013.01.009 10.1371/journal.pone.0095912 10.1002/path.4550 10.1007/s10549-020-05810-3 10.18632/oncotarget.23607 10.1016/j.ygyno.2020.07.030 10.1002/jcp.27425 10.1016/j.ejca.2020.02.007 10.1016/j.yane.2012.02.046 10.1016/j.prp.2017.11.023 10.3390/cancers11050726 10.3390/jcm5050051 10.1038/bjc.2015.177 10.1158/1535-7163.MCT-18-0584 10.1007/s11684-018-0656-6 10.3390/cancers12082199 10.1038/bjc.2015.287 10.18632/oncotarget.3184 10.1111/his.13496 10.1016/j.bbcan.2017.06.006 10.1007/s00384-020-03548-4 10.1038/nrc.2017.118 10.1016/j.cmpb.2013.05.018 10.1016/j.canlet.2017.01.041 10.1016/j.canlet.2015.07.039 10.1186/s12943-020-01276-5 10.1186/s12943-015-0295-3 10.1111/jgh.12752 10.1038/s41568-021-00376-8 10.1158/0008-5472.CAN-18-2019 10.18231/j.jdpo.2019.024 10.1002/hed.23380 10.1158/1078-0432.CCR-15-1434 10.1007/s00428-017-2071-9 10.7150/jca.46093 10.1111/his.13805 10.1038/s41571-020-0422-y 10.1038/modpathol.2017.46 10.1016/j.neo.2014.10.006 10.4103/IJPM.IJPM_120_18 10.33545/pathol.2019.v2.i1c.25 10.1038/nrc2620 10.1158/1078-0432.CCR-15-0876 10.1007/s10549-015-3333-3 10.18632/oncotarget.23144 10.1007/s12032-016-0747-7 10.1007/s12672-014-0180-3 10.1111/jop.13118 10.1002/path.4416 10.1038/s41580-018-0018-x 10.3892/ol.2014.1781 10.1166/ch.2013.1004 10.3322/caac.21708 10.1007/s10911-010-9181-1 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
| Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
| DBID | 0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/07853890.2022.2070272 |
| DatabaseName | Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | T. Huang et al |
| EISSN | 1365-2060 |
| EndPage | 1312 |
| ExternalDocumentID | oai_doaj_org_article_6a19482d2fba422d954e2343ade75be1 PMC9103277 35535687 10_1080_07853890_2022_2070272 2070272 |
| Genre | Review Article Journal Article Review |
| GroupedDBID | --- 00X 03L 0YH 23M 36B 4.4 5GY 5RE AALUX ABLKL ABUPF ACENM ACGEJ ACGFS ADCVX ADRBQ ADXPE AENEX AEOZL AFKVX AGYJP AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO EBD EBS EMB EMOBN F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- OK1 P2P RPM SV3 TDBHL TFDNU TFL TFW V1S WH7 ~1N AAFWJ AAYXX CITATION .55 .GJ 34G 39C 3O- 53G 5VS AALIY AAORF AAPXX ABWCV ABZEW ADFZZ AFFNX AFLEI AJVHN AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE DWTOO ECM EIF EJD JENTW M44 NPM NUSFT OVD QQXMO TEORI X7M ZGI ZXP 7X8 5PM |
| ID | FETCH-LOGICAL-c534t-49ff7b5be4a4dd2f16e09dede9eb71e18b47b5fa825698b2ab515eb42c360fd3 |
| IEDL.DBID | DOA |
| ISSN | 0785-3890 1365-2060 |
| IngestDate | Mon Sep 01 19:40:16 EDT 2025 Thu Aug 21 13:52:50 EDT 2025 Thu Jul 10 17:22:43 EDT 2025 Mon Jul 21 06:08:46 EDT 2025 Wed Sep 03 16:39:34 EDT 2025 Thu Apr 24 23:10:38 EDT 2025 Wed Dec 25 09:05:37 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | tumour budding epithelial–mesenchymal transition Breast cancer |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c534t-49ff7b5be4a4dd2f16e09dede9eb71e18b47b5fa825698b2ab515eb42c360fd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 These authors contributed equally to this work. |
| OpenAccessLink | https://doaj.org/article/6a19482d2fba422d954e2343ade75be1 |
| PMID | 35535687 |
| PQID | 2661955191 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | crossref_primary_10_1080_07853890_2022_2070272 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9103277 pubmed_primary_35535687 doaj_primary_oai_doaj_org_article_6a19482d2fba422d954e2343ade75be1 proquest_miscellaneous_2661955191 informaworld_taylorfrancis_310_1080_07853890_2022_2070272 crossref_citationtrail_10_1080_07853890_2022_2070272 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-31 |
| PublicationDateYYYYMMDD | 2022-12-31 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Annals of medicine (Helsinki) |
| PublicationTitleAlternate | Ann Med |
| PublicationYear | 2022 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | e_1_3_5_29_1 e_1_3_5_27_1 e_1_3_5_25_1 Dawson H (e_1_3_5_8_1) 2015; 2 e_1_3_5_23_1 e_1_3_5_44_1 Zhaoji L (e_1_3_5_48_1) 2015; 16 e_1_3_5_46_1 e_1_3_5_40_1 e_1_3_5_42_1 e_1_3_5_9_1 e_1_3_5_21_1 e_1_3_5_5_1 e_1_3_5_7_1 e_1_3_5_18_1 e_1_3_5_39_1 e_1_3_5_16_1 e_1_3_5_37_1 e_1_3_5_14_1 e_1_3_5_35_1 e_1_3_5_12_1 e_1_3_5_33_1 e_1_3_5_56_1 e_1_3_5_58_1 Chad C (e_1_3_5_50_1) 2013; 5 e_1_3_5_52_1 Gabal SM (e_1_3_5_15_1) 2018; 12 e_1_3_5_54_1 e_1_3_5_10_1 e_1_3_5_31_1 e_1_3_5_28_1 e_1_3_5_26_1 e_1_3_5_24_1 e_1_3_5_22_1 e_1_3_5_45_1 e_1_3_5_47_1 e_1_3_5_49_1 Roizen MF. (e_1_3_5_3_1) 2012; 2012 e_1_3_5_2_1 e_1_3_5_60_1 e_1_3_5_41_1 e_1_3_5_43_1 e_1_3_5_20_1 e_1_3_5_4_1 e_1_3_5_6_1 e_1_3_5_17_1 e_1_3_5_38_1 e_1_3_5_13_1 e_1_3_5_36_1 e_1_3_5_11_1 e_1_3_5_34_1 e_1_3_5_55_1 e_1_3_5_57_1 e_1_3_5_19_1 Jente VS (e_1_3_5_59_1) 2018 e_1_3_5_51_1 e_1_3_5_53_1 e_1_3_5_32_1 e_1_3_5_30_1 |
| References_xml | – ident: e_1_3_5_18_1 doi: 10.1016/j.prp.2013.01.009 – ident: e_1_3_5_34_1 doi: 10.1371/journal.pone.0095912 – ident: e_1_3_5_40_1 doi: 10.1002/path.4550 – ident: e_1_3_5_55_1 doi: 10.1007/s10549-020-05810-3 – ident: e_1_3_5_53_1 doi: 10.18632/oncotarget.23607 – volume: 2 start-page: 11 year: 2015 ident: e_1_3_5_8_1 article-title: Molecular and pathogenetic aspects of tumor budding in colorectal cancer publication-title: Front Med (Lausanne) – ident: e_1_3_5_13_1 doi: 10.1016/j.ygyno.2020.07.030 – ident: e_1_3_5_44_1 doi: 10.1002/jcp.27425 – ident: e_1_3_5_54_1 doi: 10.1016/j.ejca.2020.02.007 – volume: 2012 start-page: 13 year: 2012 ident: e_1_3_5_3_1 article-title: Hallmarks of cancer: the next generation publication-title: Yearbook Anesthesiol Pain Manage doi: 10.1016/j.yane.2012.02.046 – ident: e_1_3_5_57_1 doi: 10.1016/j.prp.2017.11.023 – ident: e_1_3_5_31_1 doi: 10.3390/cancers11050726 – ident: e_1_3_5_5_1 doi: 10.3390/jcm5050051 – ident: e_1_3_5_41_1 doi: 10.1038/bjc.2015.177 – volume: 16 start-page: 32 year: 2015 ident: e_1_3_5_48_1 article-title: Hua-feng Z. Hypoxia-inducible factor 1 and breast cancer metastasis publication-title: Biomed Biotechnol – ident: e_1_3_5_60_1 doi: 10.1158/1535-7163.MCT-18-0584 – ident: e_1_3_5_26_1 doi: 10.1007/s11684-018-0656-6 – ident: e_1_3_5_12_1 doi: 10.3390/cancers12082199 – ident: e_1_3_5_19_1 doi: 10.1038/bjc.2015.287 – ident: e_1_3_5_49_1 doi: 10.18632/oncotarget.3184 – ident: e_1_3_5_51_1 doi: 10.1111/his.13496 – ident: e_1_3_5_27_1 doi: 10.1016/j.bbcan.2017.06.006 – ident: e_1_3_5_7_1 doi: 10.1007/s00384-020-03548-4 – ident: e_1_3_5_24_1 doi: 10.1038/nrc.2017.118 – ident: e_1_3_5_42_1 doi: 10.1016/j.cmpb.2013.05.018 – ident: e_1_3_5_43_1 doi: 10.1016/j.canlet.2017.01.041 – ident: e_1_3_5_45_1 doi: 10.1016/j.canlet.2015.07.039 – ident: e_1_3_5_28_1 doi: 10.1186/s12943-020-01276-5 – ident: e_1_3_5_36_1 doi: 10.1186/s12943-015-0295-3 – ident: e_1_3_5_39_1 doi: 10.1111/jgh.12752 – ident: e_1_3_5_23_1 doi: 10.1038/s41568-021-00376-8 – ident: e_1_3_5_29_1 doi: 10.1158/0008-5472.CAN-18-2019 – ident: e_1_3_5_14_1 doi: 10.18231/j.jdpo.2019.024 – ident: e_1_3_5_6_1 doi: 10.1002/hed.23380 – volume: 12 start-page: EC25 issue: 5 year: 2018 ident: e_1_3_5_15_1 article-title: Tumour budding and MMP-2 expression in breast invasive ductal carcinoma publication-title: J Clin Diagnos Res – ident: e_1_3_5_46_1 doi: 10.1158/1078-0432.CCR-15-1434 – ident: e_1_3_5_56_1 doi: 10.1007/s00428-017-2071-9 – ident: e_1_3_5_11_1 doi: 10.7150/jca.46093 – start-page: 6195 year: 2018 ident: e_1_3_5_59_1 article-title: Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer publication-title: Oncogene – ident: e_1_3_5_35_1 doi: 10.1111/his.13805 – ident: e_1_3_5_21_1 doi: 10.1038/s41571-020-0422-y – ident: e_1_3_5_4_1 doi: 10.1038/modpathol.2017.46 – ident: e_1_3_5_58_1 doi: 10.1016/j.neo.2014.10.006 – ident: e_1_3_5_20_1 doi: 10.4103/IJPM.IJPM_120_18 – ident: e_1_3_5_17_1 doi: 10.33545/pathol.2019.v2.i1c.25 – ident: e_1_3_5_33_1 doi: 10.1038/nrc2620 – ident: e_1_3_5_47_1 doi: 10.1158/1078-0432.CCR-15-0876 – ident: e_1_3_5_16_1 doi: 10.1007/s10549-015-3333-3 – ident: e_1_3_5_52_1 doi: 10.18632/oncotarget.23144 – ident: e_1_3_5_38_1 doi: 10.1007/s12032-016-0747-7 – ident: e_1_3_5_9_1 doi: 10.1007/s12672-014-0180-3 – ident: e_1_3_5_10_1 doi: 10.1111/jop.13118 – ident: e_1_3_5_22_1 doi: 10.1002/path.4416 – volume: 5 start-page: 187 year: 2013 ident: e_1_3_5_50_1 article-title: The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective publication-title: Cancer Manag Res – ident: e_1_3_5_30_1 doi: 10.1038/s41580-018-0018-x – ident: e_1_3_5_37_1 doi: 10.3892/ol.2014.1781 – ident: e_1_3_5_25_1 doi: 10.1166/ch.2013.1004 – ident: e_1_3_5_2_1 doi: 10.3322/caac.21708 – ident: e_1_3_5_32_1 doi: 10.1007/s10911-010-9181-1 |
| SSID | ssj0002710 |
| Score | 2.4826837 |
| SecondaryResourceType | review_article |
| Snippet | Breast cancer (BC) is a group of markedly heterogeneous tumours. There are many subtypes with different biological behaviours and clinicopathological... |
| SourceID | doaj pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1303 |
| SubjectTerms | Biomarkers, Tumor Breast cancer Breast Neoplasms - diagnosis Epithelial-Mesenchymal Transition Female Humans Oncology Prognosis Review Tumor Microenvironment tumour budding |
| SummonAdditionalLinks | – databaseName: Taylor & Francis Open Access dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQkVAvFc92KSAjcV2IX3HMDRDVCqmcFglOxs92pZJFSZbf35k8VrtVqx44Js5YtmfGMxPPfCbkXaGDyiGxec4KAhTDQKVUgMBVqBiKIrtssMD5_Hu5-CG__VRTNmE7plViDJ0HoIh-r0bldr6dMuI-gFUDNTUFRHcca6k0hFawCz_kKK0g0sWvxXYz5roHJECSOdJMRTx3dbNnnnoU_xsYprd5ojcTKncs1NljcjS6lvTTIAtPyINUPyWPzsfD82fk93IDcX5D_SaiwaKrljpar_-lK_oHk3QauqqpxyT1jgYUhuYjBfeQTsWTdOewm8Li0QGPhMJA-3rN9jlZnn1dflnMxwsW5kEJ2QFrctZe-SSdjJFnVqbCxBSTSV6zxCovoTk7iCJLU3nuPHg_yUseRFnkKF6Qg3pdpxNCmYg5VtBNKpUMpnKVZxiJgARwJJ8ROS2rDSP4ON6BcWXZhFE6csMiN-zIjRl5vyX7O6Bv3EfwGXm2_RjBs_sX6-bCjrpoS8eMrDhM2DvJeTRKJi6kcDFpWAw2I2aX47br_53k4aITK-4ZwNtJPCwoKp6-uDqtN61FT8iAf2qg_-NBXLbDBKdPqLLSM6L3BGlvHvst9eqyBwM3iIio9cv_GPMpOcTHAb7yFTnomk16Da5W59_0ynQNHLweHw priority: 102 providerName: Taylor & Francis |
| Title | Tumour budding is a novel marker in breast cancer: the clinical application and future prospects |
| URI | https://www.tandfonline.com/doi/abs/10.1080/07853890.2022.2070272 https://www.ncbi.nlm.nih.gov/pubmed/35535687 https://www.proquest.com/docview/2661955191 https://pubmed.ncbi.nlm.nih.gov/PMC9103277 https://doaj.org/article/6a19482d2fba422d954e2343ade75be1 |
| Volume | 54 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELagB8QFtUAhbYmMxDXtrh_rdW9tRRUhlVOQysn1U0QqG5Rs-P2d8e5GSYWUC1d7bdkz4535bM9nQr4UysvkYzlJSQJA0SUsKekBuHIZfFEkmzQmON99r6Y_xLd7eb_11BfeCevogTvBXVQWYHbNAkvOCsaCliIyLrgNUUkXM_ABnzeAqf4fzFTmIQD_JyfgkoshdwdZtaEMiwAbMszEUvAx2_FKmbz_GXXpvwLQ5_cotxzT7SF500eU9KqbyRF5EZu35NVdf2b-jjzM1gDvl9StA_opOl9RS5vF3_hIf-PdnCWdN9Th3fSWerSB5SWFqJAOOZN064yb2ibQjoaEwkBzmubqPZndfp3dTCf9uwoTL7loQSMpKQfCE1YEEGxZxUKHGKKOTpWxrJ2A6mQBPFa6dsw6CHqiE8zzqkiBH5ODZtHEj4SWPKRQQzexksLr2tauRAACimfYfETEIFbje85xfPri0ZQDNWmvDYPaML02RuR80-xPR7qxr8E16mzzMXJm5wKwJNNbktlnSSOitzVu2rxlkrr3TQzfM4DPg3kYWJ946GKbuFivDAZAGsJSDf1_6MxlM0yI9bisajUiaseQduaxW9PMf2UOcI1EiEqd_I-Jn5LXOJeOvvKMHLTLdfwEoVbrxuRl8XM6zmtrnHfCngBcciNd |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELZQkYAL4k0oDyNxDaxf63VvBVEFaHoKUjkZPyFS2aDNht_fmX1ESQXqget6x7I9M54Ze-YzIW8KHVQOiU1zVhCgGAYqpQIErkLFUBTZZYMFzvOzcvZVfj5X5zu1MJhWiTF07oEiur0alRsPo8eUuHdg1kBPTQHhHcdiKg2xFWzDNxUYX3y-ofg22-7GXHeIBEgyRZqxiudf3ezZpw7G_wqI6d9c0asZlTsm6uQeuTv4lvS4F4b75EaqH5Bb8-H2_CH5vthAoN9Qv4losehyTR2tV3_SBf2FWToNXdbUY5Z6SwNKQ3NEwT-kY_Uk3bntprB6tAckoTDQrmBz_YgsTj4uPsymwwsL06CEbIE3OWuvfJJOxsgzK1NhYorJJK9ZYpWX0JwdhJGlqTx3Htyf5CUPoixyFI_JQb2q01NCmYg5VtBNKpUMpnKVZxiKgAhwJJ8QOS6rDQP6OD6CcWHZCFI6cMMiN-zAjQl5uyX73cNvXEfwHnm2_RnRs7sPq-aHHZTRlo4ZWXGYsHeS82iUTFxI4WLSsBhsQswux23bHZ7k_qUTK64ZwOtRPCxoKl6_uDqtNmuLrpABB9VA_096cdkOE7w-ocpKT4jeE6S9eey31MufHRq4QUhErZ_9x5hfkduzxfzUnn46-3JI7mBTj2X5nBy0zSa9AL-r9S87xboEptghkw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZjxMxDI7QIq14QdyU5QgSr4XJNZnsG1dVjl3xUCR4CjmXSst0NZ3y-7HnqNoVaB94nYwjT2zH9sT-QsiLQgeVQ2LTnBUkKIaBSakAiatQMRRFdtlgg_PJaTn_Kj9-U2M14Xooq8QcOvdAEd1ejcZ9EfNYEfcKvBqYqSkgu-PYS6UhtYJd-LqqwNeDShff59vNmOsOkABJpkgzNvH8a5o999Sh-F_CMP1bJHq5oHLHQ81ukZtDaElf97pwm1xL9R1yeDIcnt8lPxYbyPMb6jcRHRZdrqmj9ep3Oqe_sEinocuaeixSb2lAZWiOKYSHdGyepDuH3RQWj_Z4JBQY7fo11_fIYvZ-8XY-HS5YmAYlZAuiyVl75ZN0MkaeWZkKE1NMJnnNEqu8hOHsIIssTeW58xD9JC95EGWRo7hPDupVnR4SykTMsYJpUqlkMJWrPMNMBDSAI_mEyHFZbRjAx_EOjHPLRozSQRoWpWEHaUzIyy3ZRY--cRXBG5TZ9mUEz-4erJozO9iiLR0zsuLwwd5JzqNRMnEhhYtJw2KwCTG7Erdt9-8k9xedWHEFA89H9bBgqHj64uq02qwtRkIG4lMD8z_o1WXLJgR9QpWVnhC9p0h737E_Ui9_dmDgBhERtX70Hzw_I4df3s3s5w-nn47IDRzpkSwfk4O22aQnEHW1_mlnV38A0uQgxQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumour+budding+is+a+novel+marker+in+breast+cancer%3A+the+clinical+application+and+future+prospects&rft.jtitle=Annals+of+medicine+%28Helsinki%29&rft.au=Huang%2C+Ting&rft.au=Bao%2C+Hui&rft.au=Meng%2C+Yu-hua&rft.au=Zhu%2C+Jian-lin&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis&rft.issn=0785-3890&rft.eissn=1365-2060&rft.volume=54&rft.issue=1&rft.spage=1303&rft.epage=1312&rft_id=info:doi/10.1080%2F07853890.2022.2070272&rft_id=info%3Apmid%2F35535687&rft.externalDocID=PMC9103277 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0785-3890&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0785-3890&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0785-3890&client=summon |